Identification of novel variants in ten patients with Hermansky-Pudlak syndrome by high-throughput sequencing. (17th February 2019)

• Record Type: Journal Article
• Authors: Bastida, Jose María; Morais, Sara; Palma-Barqueros, Veronica; Benito, Rocio; Bermejo, Nuria; Karkucak, Mutlu; Trapero-Marugan, Maria; Bohdan, Natalia; Pereira, Mónica; Marin-Quilez, Ana; Oliveira, Jorge; Yucel, Yusuf; Santos, Rosario; Padilla, Jose; Janusz, Kamila; Lau, Catarina; Martin-Izquierdo, Marta; Couto, Eduarda; Francisco Ruiz-Pividal, Juan; Vicente, Vicente; Hernández-Rivas, Jesus Maria; González-Porras, Jose Ramon; Luisa Lozano, Maria; Lima, Margarida; Rivera, Jose
• Is Part Of: Annals of medicine. Volume 51:Number 2(2019)
• Page Start: 141
• Page End: 148
• Publication Date: 2019-02-17
• Subjects: Hermansky-Pudlak syndrome -- high-throughput nucleotide sequencing -- blood platelet disorders; Medicine -- Periodicals; 610
• DOI: 10.1080/07853890.2019.1587498
• Languages: English
• ISSNs: 0785-3890

Abstract

Abstract: Background: Hermansky-Pudlak syndrome (HPS) is a rare inherited platelet disorder characterized by bleeding diathesis, oculocutaneous albinism (OCA) and a myriad of often-serious clinical complications. Methods: We established the clinical and laboratory phenotype and genotype of six unrelated pedigrees comprising ten patients with clinical suspicion of HPS; including platelet aggregation, flow cytometry, platelet dense granule content, electron microscopy and high-throughput sequencing (HTS). Results: The clinical presentation showed significant heterogeneity and no clear phenotype-genotype correlations. HTS revealed two known and three novel disease-causing variants. The Spanish patients carried a homozygous p.Pro685Leufs17* deletion ( n = 2) in HPS4, or the novel p.Arg822* homozygous variant ( n = 1) in HPS3 . In the case of two Turkish sisters, a novel missense homozygous HPS4 variant (p.Leu91Pro) was found. In two Portuguese families, genetic studies confirmed a previously reported nonsense variant (p.Gln103*) in DTNBP1 in three patients and a novel duplication (p.Leu22Argfs*33) in HPS6 in two unrelated patients. Conclusions: Our findings expand the mutational spectrum of HPS, which may help in investigating phenotype-genotype relationships and assist genetic counselling for affected individuals. This approach is a proof of principle that HTS can be considered and used in the first-line diagnosis of patients with biological and clinical manifestations suggestive of HPS. Key messages: We established the relationships between the clinical and laboratory phenotype and genotype of six unrelated pedigrees comprising ten patients with clinical suspicion of HPS. Molecular analysis is useful in confirming the diagnosis and may offer some prognostic information that will aid in optimizing monitoring and surveillance for early detection of end-organ damage. This approach is a proof of principle that HTS can be considered and used in the first-line diagnosis of patients with biological and clinical manifestations suggestive of HPS.